Published in Cancer Weekly, March 24th, 2009
"In contrast to RKIP, which disrupts the RAF1-MEK interaction, PEBP4 forms ternary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.